STOCK TITAN
  1. Home
  2. News
  3. XAIR

Beyond Air Inc - XAIR STOCK NEWS

IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
covid-19
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
conferences clinical trial
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® To Participate in Three Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
clinical trial
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023
earnings
Stock XAIR logo
Beyond Air Inc

Nasdaq:XAIR

XAIR Rankings

#5897 Ranked by Market Cap
#5085 Ranked by Stock Gains
N/A Ranked by Dividends

XAIR Stock Data

Other Industrial Machinery Manufacturing
Manufacturing
Link
US
Garden City

About XAIR

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.